IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Voorraadrapport

Marktkapitalisatie: US$2.5b

IDEAYA Biosciences Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yujiro Hata

Algemeen directeur

US$9.5m

Totale compensatie

Percentage CEO-salaris7.36%
Dienstverband CEO11yrs
Eigendom CEO0.8%
Management gemiddelde ambtstermijn2.5yrs
Gemiddelde ambtstermijn bestuur7.6yrs

Recente managementupdates

Recent updates

Seeking Alpha • Jun 11

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

Summary IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal melanoma and robust clinical progress. The company's darovasertib + crizotinib met the mPFS primary endpoint in 1st-line HLA*A2-negative mUM, supporting an RTOR NDA Accelerated Approval submission filing. Upcoming catalysts include NDA filing submission completion of darovasertib in H2 2026, label expansion data for HLA*A2-positive mUM, and further neoadjuvant/adjuvant melanoma updates. The company boasts a cash runway into 2030, recently raised $300M, and retains U.S. rights plus milestone/royalty upside through its Servier partnership. Read the full article on Seeking Alpha
Analyseartikel • Jun 02

News Flash: Analysts Just Made A Substantial Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Forecasts

IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • May 08

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates

IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders are probably feeling a little disappointed, since its shares fell...
Analyseartikel • May 07

Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates

Market forces rained on the parade of IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders today, when the analysts...
Analyseartikel • Jul 28

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 16

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Summary IDEAYA Biosciences' valuation has declined over 50% since mid-2024, prompting a re-evaluation of its investment potential. The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutations, showing promising clinical activity. With over $1 billion in cash and other investments, IDYA has 4–5 years of operational liquidity. Strength: Strong liquidity. Risk: Heavy reliance on key data catalysts for future success. Read the full article on Seeking Alpha
Analyseartikel • Apr 13

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 10

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Summary Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uveal melanoma; mPFS data expected end of 2025. Darovasertib is also being evaluated in another phase 2 study as a monotherapy targeting neoadjuvant uveal melanoma patients, with data expected in 2025. The global uveal melanoma treatment market is projected to reach $3.22 billion by the end of 2034. IDYA is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028, reducing near-term dilution risk. Read the full article on Seeking Alpha
Analyseartikel • Jan 03

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 04

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Summary Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead candidate, Darovasertib, shows promising efficacy in metastatic uveal melanoma, especially in combination with crizotinib, addressing a significant unmet medical need. IDE397, another key asset, demonstrated positive interim data in MTAP-deletion cancers, showing a 39% ORR and a strong safety profile. With a market cap of $2.37bn and a cash runway into 2028, IDYA is financially well-positioned, despite the inherent risks of late-stage studies. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Summary IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates in MTAP-deleted solid tumors. Strategic partnerships with Pfizer, Amgen, Gilead, and GSK validate IDEAYA's technology and offer substantial potential milestone payments. IDE397 shows a 94% disease control rate in Phase 2 trials for MTAP-deleted tumors, with favorable safety and efficacy profiles, positioning it as a potential first-in-class treatment. IDYA has a robust cash runway and reasonable valuation, which is why I rate it a "buy" for long-term biotech investors. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Summary Ideaya Biosciences is a cancer-focused biotech with promising pipeline candidates darovasertib and IDE397 targeting uveal melanoma and MTAP-deleted cancers. Darovasertib has shown strong results in phase 2 trials for uveal melanoma, while IDE397 demonstrated positive phase 2 data for MTAP-deleted NSCLC and urothelial cancer. With a solid financial position and potential for accelerated approvals, IDYA presents a compelling investment opportunity, although the current valuation may be high. Read the full article on Seeking Alpha
Seeking Alpha • Jun 18

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and has a fortress balance sheet. An updated analysis around Ideaya Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Analyseartikel • Feb 22

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Feb 16

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Summary IDEAYA Biosciences' stock has increased by 57% since September, outperforming the S&P 500. PRMT5 inhibitors have gained attention in the biotech industry, with Bristol Myers paying $5.8 billion, in part, for Mirati's PRMT5 medication. IDEAYA's second lead drug, IDE397, is a PRMT5 inhibitor being studied in combination with an Amgen drug, with worldwide commercial rights retained by IDEAYA. Given the company's strategic positioning and the high unmet medical need in its target indications, IDEAYA appears to be a promising investment with significant upside potential. Read the full article on Seeking Alpha

Analyse CEO-vergoeding

Hoe is Yujiro Hata's beloning veranderd ten opzichte van IDEAYA Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2026n/an/a

-US$140m

Dec 31 2025US$10mUS$700k

-US$114m

Sep 30 2025n/an/a

-US$161m

Jun 30 2025n/an/a

-US$332m

Mar 31 2025n/an/a

-US$307m

Dec 31 2024US$17mUS$646k

-US$274m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$154m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$6mUS$598k

-US$113m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$570k

-US$59m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$4mUS$544k

-US$50m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$2mUS$510k

-US$34m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$2mUS$457k

-US$42m

Compensatie versus markt: De totale vergoeding ($USD 9.51M ) Yujiro } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.94M ).

Compensatie versus inkomsten: De vergoeding van Yujiro is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Yujiro Hata (52 yo)

11yrs
Tenure
US$9,512,640
Compensatie

Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Yujiro Hata
Founder11yrsUS$9.51m0.79%
$ 20.0m
Joshua Bleharski
Chief Financial Officer1.1yrsUS$4.15m0%
$ 0
Andres Briseno
Chief Accounting Officer2.9yrsUS$1.65m0.030%
$ 766.9k
Michael White
Chief Scientific Officer4.7yrsUS$3.32m0%
$ 0
Douglas Snyder
Chief Legal Officer1.8yrsUS$1.13m0.0024%
$ 60.3k
Darrin Beaupre
Chief Medical Officer3.6yrsUS$3.33m0%
$ 0
Paul Barsanti
Chief Technology Officer3.4yrsgeen gegevensgeen gegevens
Francine Zelaya
Senior VP & Head of Human Resources2yrsgeen gegevensgeen gegevens
Mick O'Quigley
Senior Vice President of Medical Writing & Project Management4.3yrsgeen gegevensgeen gegevens
Daniel Simon
Chief Business Officer1.8yrsgeen gegevensgeen gegevens
Stuart Dorman
Chief Commercial Officer1.5yrsUS$3.42mgeen gegevens
Jasgit Sachdev
Senior Vice President of Late Phase Clinical Development & Strategy1.4yrsgeen gegevensgeen gegevens
2.5yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van IDYA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Yujiro Hata
Founder11yrsUS$9.51m0.79%
$ 20.0m
Wendy Yarno
Independent Director6.5yrsUS$344.16k0%
$ 0
Jeffrey Stein
Independent Director10.7yrsUS$351.66k0.062%
$ 1.6m
Frank McCormick
Chair of Scientific Advisory Board7.3yrsgeen gegevensgeen gegevens
Scott William Morrison
Independent Director7.9yrsUS$351.66k0%
$ 0
Catherine Mackey
Independent Director4.2yrsUS$334.16k0%
$ 0
Trey Ideker
Member of Scientific Advisory Board10.1yrsgeen gegevensgeen gegevens
William Sellers
Member of Scientific Advisory Board7.3yrsgeen gegevensgeen gegevens
Elizabeth Swisher
Member of Scientific Advisory Board10.1yrsgeen gegevensgeen gegevens
Terry Rosen
Independent Chairman of the Board10.4yrsUS$379.16k0.0093%
$ 236.8k
Malcolm Hampton
Independent Director6yrsUS$331.66k0%
$ 0
Karlene Cimprich
Member of Scientific Advisory Board3.5yrsgeen gegevensgeen gegevens
7.6yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IDYA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/06/16 21:02
Aandelenkoers aan het einde van de dag2026/06/15 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

IDEAYA Biosciences, Inc. wordt gevolgd door 31 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Madhu KumarBaird
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG